VIDEO: Tovorafenib for low-grade gliomas shows decreased tumor growth in phase 2 study

ByCassie Kline, MD, MAS

ByGeorgia I Salvaryn

Fact checked byMindy Valcarcel, MS

PHILADELPHIA — In this video, Cassie Kline, MD, MAS, discusses the results of the FIREFLY-1 (NCT04775485) trial she presented at International Symposium on Pediatric Neuro-Oncology.

The phase 2 study observed the treatment of pediatric low-grade gliomas using tovorafenib (DAY101, Day One Biopharmaceuticals) to decrease growth velocity of the central nervous system tumors.

“This drug recently received accelerated approval from the FDA for this indication, which is really exciting because it is so rare that we get a pediatric-specific indication for targeted drugs,” Kline, a pediatric neuro-oncology attending and director of neuro-oncology clinical research at Children’s Hospital of Philadelphia, said.

Reference:

Kline C, et al. Abstract LGG-40. Presented at: International Symposium on Pediatric Neuro-Oncology; June 28-July 2, 2024; Philadelphia.

Published by:

Sources/Disclosures

Collapse

Disclosures: Kline reports grants from and/or clinical trial contracts with Bristol Myers Squibb, Cannonball Kids’ cancer Foundation, Chimerix, Curis, Day One Biopharmaceuticals, Ipsen, Kazia Therapeutics, Kortney Rose Foundation, Midatech Pharma and Regeneron Pharmaceuticals.

Take Homes from ISPNO

Read more

VIDEO: Tovorafenib for low-grade gliomas shows decreased tumor growth in phase 2 study

Reference:

Related Content